These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

10819 related items for PubMed ID: 1337321

  • 1. Modifications of the binding properties of the human VIP receptor of IGR39 cells by sulfhydryl reagents.
    Fouchier F, Forget P, Pic P, Marvaldi J, Pichon J.
    Eur J Cell Biol; 1992 Dec; 59(2):382-8. PubMed ID: 1337321
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of vasoactive intestinal peptide (VIP) binding on human melanoma cells IGR39 by nitric oxide: cGMP is not involved.
    Fouchier F, Pichon J, Forget P.
    Eur J Cell Biol; 1994 Jun; 64(1):71-7. PubMed ID: 7957315
    [Abstract] [Full Text] [Related]

  • 3. Characterization of the vasoactive intestinal peptide receptor in rat submandibular gland: radioligand binding assay in membrane preparations.
    Turner JT, Bylund DB.
    J Pharmacol Exp Ther; 1987 Sep; 242(3):873-81. PubMed ID: 2821229
    [Abstract] [Full Text] [Related]

  • 4. Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines.
    Bellan C, Pic P, Marvaldi J, Fantini J, Pichon J.
    Second Messengers Phosphoproteins; 1991 Sep; 13(4):163-71. PubMed ID: 1667418
    [Abstract] [Full Text] [Related]

  • 5. Effects of thiol-reagents on [3H]alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to rat telencephalic membranes.
    Terramani T, Kessler M, Lynch G, Baudry M.
    Mol Pharmacol; 1988 Aug; 34(2):117-23. PubMed ID: 2901029
    [Abstract] [Full Text] [Related]

  • 6. Restricted localization of functional vasoactive intestinal peptide (VIP) receptors in in vitro differentiated human colonic adenocarcinoma cells (HT29-D4).
    Fantini J, Martin JM, Luis J, Rémy L, Tirard A, Marvaldi J, Pichon J.
    Eur J Cell Biol; 1988 Aug; 46(3):458-65. PubMed ID: 2846304
    [Abstract] [Full Text] [Related]

  • 7. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 2. Effect of VIP on cAMP production and on cell-surface VIP-binding sites.
    Martin JM, Luis J, Marvaldi J, Pichon J, Pic P.
    Eur J Biochem; 1989 Mar 15; 180(2):435-9. PubMed ID: 2538331
    [Abstract] [Full Text] [Related]

  • 8. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
    Zawilska JB, Niewiadomski P, Nowak JZ.
    Gen Comp Endocrinol; 2004 Jun 15; 137(2):187-95. PubMed ID: 15158130
    [Abstract] [Full Text] [Related]

  • 9. Effects of sulfhydryl modification reagents on the kinase activity of the epidermal growth factor receptor.
    Woltjer RL, Staros JV.
    Biochemistry; 1997 Aug 12; 36(32):9911-6. PubMed ID: 9245424
    [Abstract] [Full Text] [Related]

  • 10. The polypeptide PHI discriminates a GTP-insensitive form of VIP receptor in liver membranes.
    Pineau N, Lelievre V, Goursaud S, Hilairet S, Waschek JA, Janet T, Muller JM.
    Neuropeptides; 2001 Apr 12; 35(2):117-26. PubMed ID: 11384207
    [Abstract] [Full Text] [Related]

  • 11. Properties of vasoactive intestinal peptide-receptor interaction in rat liver membranes.
    Guerrero JM, Prieto JC, Ramírez-Cárdenas R, Calvo JR, Goberna R.
    Rev Esp Fisiol; 1981 Mar 12; 37(1):1-8. PubMed ID: 6113623
    [Abstract] [Full Text] [Related]

  • 12. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 1. Molecular characterization of the binding site.
    Luis J, Martin JM, el Battari A, Reynier M, Marvaldi J, Pichon J.
    Eur J Biochem; 1989 Mar 15; 180(2):429-33. PubMed ID: 2538330
    [Abstract] [Full Text] [Related]

  • 13. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
    Jiang S, Kopras E, McMichael M, Bell RH, Ulrich CD.
    Cancer Res; 1997 Apr 15; 57(8):1475-80. PubMed ID: 9108448
    [Abstract] [Full Text] [Related]

  • 14. [Autoradiographic localization and characterization of the ocular binding sites of the VIP (vasoactive intestinal peptide) in albino rats and rabbits].
    Denis P, Dussaillant M, Elena PP, Nordmann JP, Rostene W, Laroche L.
    Ophtalmologie; 1990 Apr 15; 4(1):30-2. PubMed ID: 2174530
    [Abstract] [Full Text] [Related]

  • 15. 125I-vasoactive intestinal peptide binding in human kidney.
    Charlton BG, Neal DE, Simmons NL.
    Miner Electrolyte Metab; 1991 Apr 15; 17(6):372-6. PubMed ID: 1823387
    [Abstract] [Full Text] [Related]

  • 16. [Vasoactive intestinal peptide receptor in a human pancreatic carcinoma cell line].
    Chen Y.
    Zhonghua Yi Xue Za Zhi; 1990 Mar 15; 70(3):135-7, 12. PubMed ID: 2163737
    [Abstract] [Full Text] [Related]

  • 17. The effects of sulfhydryl-modifying reagents on cholecystokinin-receptor interactions in guinea pig gastric glands.
    Ramani N, Praissman M.
    Endocrinology; 1989 Jun 15; 124(6):2821-9. PubMed ID: 2721447
    [Abstract] [Full Text] [Related]

  • 18. The effects of ribavirin on the GTP level and the VIP receptor dynamic of human IGR39 cells.
    Fouchier F, Forget P, Bellan C, Marvaldi J, Champion S, Pichon J.
    J Recept Signal Transduct Res; 1996 Jun 15; 16(1-2):39-58. PubMed ID: 8771530
    [Abstract] [Full Text] [Related]

  • 19. Structural and functional analysis of the human vasoactive intestinal peptide receptor glycosylation. Alteration of receptor function by wheat germ agglutinin.
    Chochola J, Fabre C, Bellan C, Luis J, Bourgerie S, Abadie B, Champion S, Marvaldi J, el Battari A.
    J Biol Chem; 1993 Feb 05; 268(4):2312-8. PubMed ID: 8381403
    [Abstract] [Full Text] [Related]

  • 20. Effect of inhibiting N-glycosylation or oligosaccharide processing on vasoactive intestinal peptide receptor binding activity and structure.
    el Battari A, Forget P, Fouchier F, Pic P.
    Biochem J; 1991 Sep 01; 278 ( Pt 2)(Pt 2):527-33. PubMed ID: 1654885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 541.